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Abstract
Background: Cervical cancer is the most common female cancer in Rwanda that, in 2011, became the first African
country to implement a national vaccination programme against human papillomavirus (HPV).
Methods: To provide a robust baseline for future evaluations of vaccine effectiveness, cervical cell specimens were
obtained from 2508 women aged 18–69 years from the general population in Kigali, Rwanda, during 2013/14. 20 % of
women were HIV-positive. Samples were used for liquid-based cytology and HPV testing (44 types) with GP5+/6+ PCR.
Results: HPV prevalence was 34 %, being highest (54 %) in women ≤19 years and decreasing to 20 % at age ≥50.
Prevalence of high risk (HR) HPV and cytological abnormalities was 22 and 11 % respectively (including 2 % with
high-grade squamous intraepithelial lesions, HSIL) decreasing with age. Age-standardised prevalence of HR HPV was 22 %
(or 19 % among HIV-negative women), and HPV16 was the most common type. Prevalence of HPV and cytological
abnormalities were significantly higher in HIV-positive than HIV-negative women, and the difference increased with age.
Other significant risk factors for HPV positivity in multivariate analyses were high lifetime number of sexual partners,
receiving cash for sex, and being a farmer. 40 % of women with HSIL were infected with HPV16/18 and there was no
significant difference between HIV-positive and HIV-negative women.
Conclusions: This study confirms Rwanda to be a setting of high prevalence of HPV and cervical disease that is
worsened by HIV. These data will serve as a robust baseline for future evaluations of HPV vaccine programme
effectiveness.
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Background
Cervical cancer represents by far the most common cancer
among females in Rwanda, and has a high age-standardised
incidence rate of approximately 42 cases per 100,000
women per year [1] that is typical of many sub-Saharan
African countries. In response to this high burden, Rwanda
became the first African country to initiate a national
vaccination programme against human papillomavirus
(HPV), the necessary cause of cervical cancer. In 2011, over
92,000 girls in primary school grade six (approximately
12 years old) were vaccinated with quadrivalent (HPV16/
18/6/11) HPV vaccine. The three-dose vaccination coverage
was estimated at 93 % in the target population [2]. During
2012 and 2013, a catch-up vaccination targeted girls also in
secondary school grade three (approximately 15 years old)
whereas from 2014, vaccination has reverted to targeting
primary school grade six only.
However, the impact of HPV vaccination on cervical
cancer will likely not be observed for 20 years at least, so
earlier evidence of vaccine programme effectiveness is
important to encourage planners in Rwanda and other
African countries to sustain their programmes. To this
end, the Rwandan Ministry of Health, in collaboration
with the International Agency for Research on Cancer
* Correspondence: clifford@iarc.fr
3International Agency for Research on Cancer, 150 cours Albert Thomas,
69372 Lyon Cedex 08, France
Full list of author information is available at the end of the article
© 2016 Ngabo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ngabo et al. BMC Infectious Diseases  (2016) 16:225 
DOI 10.1186/s12879-016-1539-6
(IARC), initiated a series of studies to evaluate the early
impact of HPV vaccination on HPV prevalence.
A pre-vaccination study of the prevalence of, and risk
factors for, HPV infection, was initiated in 2011 according
to the standard protocol of the IARC HPV prevalence
surveys [3]. Cervicovaginal samples were collected from
women aged 18–69 years living in the capital, Kigali, with
a particular effort to oversample women ≤25 years of age
in whom the impact of vaccination on HPV prevalence
should be seen the earliest. The influence of HIV positiv-
ity, which is known to be an important determinant of
HPV prevalence and may affect the future effectiveness of
HPV vaccination, was also evaluated.
Methods
Population
Between July 2013 and May 2014, a survey was con-
ducted by the Ministry of Health of Rwanda in collabor-
ation with the IARC, Lyon, France. The study aim was
to enrol 2500 women from the general population using
an age-stratified approach, namely 1000 women aged
below 25 years old, 500 women aged 25 to 29 years old,
200 women in each 5-year age group between 30–34
and 45–49 years, and 200 women aged ≥50 years. All
mentally and physically competent women were eligible
for the study, regardless of their marital status, with
exception of those who were known to be pregnant.
All participants were residents of Nyarugenge District,
Kigali and were recruited in two ways: 1) A population-
based invitation of women aged 18–69 years residing in
pre-defined areas of Nyarugenge District was made
through community workers and community meetings.
Women were invited to attend the Reproductive Health
Department of the district hospital (Muhima). Participation
rates are difficult to estimate due to the uncertainty on the
number of women who had been reached by the informa-
tion campaign. 2) An additional opportunistic approach
was used to recruit women aged ≤29 years who were spon-
taneously attending Muhima hospital or eight other health
centers in the Nyarugenge District (Muhima, Butamwa,
Rugarama, Mwendo, Corum, Gitega, Kabusunzu, Biryogo).
Principal reasons for consultation were family planning,
childhood vaccination, post-natal care services and HIV-
related services. Study procedures were undertaken in the
centre where the woman was consulting and very few
refusals were recorded.
Following signature of an informed consent form, a
structured risk questionnaire was administered to all study
participants, and data transferred electronically to IARC
via a specifically designed on-line webpage/application.
A cytobrush (Cervex-Brush, Rovers Medical Devices
B.V., The Netherlands) was used for the collection of
exfoliated cervical cells from the endocervix and ectocer-
vix for all women. The brush containing cellular material
was placed in a vial containing PreservCyt medium
(Cytyc, Boxbourough, MA, USA) and stored at +4C
until shipment.
Women aged ≥30 years old also underwent screen-
ing by visual inspection with acetic acid (VIA).
Women with visible abnormalities of the cervix, and/
or who were positive for high risk (HR) HPV infec-
tion (for which results became available at a later
date, see below) were to be recalled for a second VIA
and treatment according to national protocols (includ-
ing cryotherapy, thermo coagulation or loop electro-
surgical excision of the cervix transition zone).
Biopsies were to be taken from all HPV-positive
women, either VIA-directed to a visible lesion or ran-
domly from 12 o’clock of the transformation zone in
the absence of a visible lesion, prior to any treatment.
Histological confirmation of cervical tissue was per-
formed at the Department of Pathology at the Kigali
Teaching University Hospital. Histology results are
the subject of ongoing quality control and, apart from
invasive cervical cancer, are not reported here.
Among women ≤29 years, no VIA was performed,
nor were HR HPV-positive women recalled for
follow-up.
HPV testing and liquid based cytology (LBC)
HPV testing was performed on exfoliated cervical
cells in the Department of Pathology at the VU Uni-
versity Medical Center, Amsterdam. DNA was
extracted from the PreservCyt sample using mag-
netic beads (Macherey-Nagel) on a robotic system
(Hamilton Robotics) according to the manufacturer’s
instructions. Beta-Globin PCR analysis was con-
ducted first to confirm the presence of human DNA
in all specimens [4]. The presence of HPV DNA was
determined by conducting a general primer GP5+/6+ −
mediated PCR, which permits the detection of a broad
spectrum of genital HPV types [5]. HPV positivity was
assessed by hybridization of PCR products in an enzyme
immunoassay with two oligoprobe cocktails that, together,
detect 44 mucosal HPV types. Subsequent HPV genotyp-
ing was conducted by reverse-line blot hybridization of
GP5+/6+ PCR products [6]. HPV types considered HR
types for this analysis were HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68 [7]; possible HR types HPV26,
30, 34, 53, 66, 67, 69, 70, 73, 82, and 85; low-risk (LR)
types HPV6, 11, 32, 40, 42, 43, 44, 54, 55, 57, 61, 64, 71,
72, 81, 83, 84, 86, 89, and 90.
Liquid-based cytology slides were prepared using a
Thin Prep 3000 processor (Cytyc-Hologic), and were
read at the Department of Pathology at the Vrije Uni-
versity Medical Center, Amsterdam, The Netherlands.
Cytological diagnoses were reported according to
CISOE-A standards [8] and were translated into
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Bethesda 2001 terminology system as 1) normal, 2)
atypical squamous cells of undetermined significance;
atypical squamous cells cannot exclude high-grade
lesion; atypical glandular cells of undetermined
significance; low-grade squamous intraepithelial
lesions (ASCUS/ASC-H/AGUS/LSIL), 3) high-grade
squamous intraepithelial lesions (HSIL), or 4) invasive
cancer.
Statistical analyses
Age-standardised HPV prevalence was computed using
the world standardised population to allow comparisons
of HPV prevalence with other IARC HPV surveys [9]. Ad-
justed prevalence ratios (PR) for HPV positivity and corre-
sponding 95 % confidence intervals (CI) were computed
using two binomial regression models with a log link, the
first adjusted for age group (<24; 25–34, 35–44 and
≥45 years) only, and a second model that adjusted add-
itionally for lifetime sexual partners (1, 2 or ≥3) and HIV
status (positive, negative, unknown). Risk trends were
assessed by considering categories as continuous variables.
Effect modification of HIV status on the association be-
tween HPV16/18 positivity and cytology was tested using
the log-likelihood ratio test.
Results
General female population
Of 2511 participants providing cervical cell samples,
2508 had valid HPV results and were included in the fol-
lowing analyses, including 1233 and 1275 recruited at
Muhima Hospital and health centres, respectively.
Ninety nine percent of women reported no HPV vaccin-
ation and 98 % no history of previous cervical cancer
screening. Among the 2391 women with a valid result
on LBC, 255 (11 %) had an abnormal cytological diagno-
sis, including 210 (9 %) with ASCUS/ASC-H/AGUS/
LSIL and 45 (2 %) with HSIL.
Overall HPV prevalence was 34 %, being 29 % among
women with normal cytology (Table 1). The prevalence
of HPV was 73 and 96 % in ASCUS/ASC-H/AGUS/LSIL
and HSIL, respectively. In total, 480 (19 %) women had
single-type and 377 (15 %) had multiple-type infections.
Crude and age-standardised prevalence of HR HPV
types was 22 %. Prevalence of possible HR HPV and LR
HPV was 10 and 15 % respectively. HPV16 was the most
common HPV type in women with normal cytology
(4 %), ASCUS/ASC-H/AGUS/LSIL (11 %), and HSIL
(29 %). HPV52 and HPV35 were the next most common
HR types in women with normal cytology and ASCUS/
ASC-H/AGUS/LSIL, compared to HPV18 and HPV58
in HSIL. Four invasive cervical cancers were found in
the study population (2 HPV16, 1 HPV33, 1 HPV nega-
tive), and two additional invasive cervical cancers among
participants without a valid sample for HPV and
cytology.
Figure 1 shows the age-specific prevalence of HPV and
cytological abnormalities, with HPV-positive women
classified hierarchically into (1) HPV16 and/or 18, (2)
other HR types and (3) LR types only. Overall HPV
prevalence was highest (54 %) among women ≤19 years,
and decreased with age, down to 20 % among women
aged ≥50 years. Prevalence of cytological abnormalities
showed no clear trend by age group.
A total of 490 (20 %) study participants self-reported
to be HIV-positive, and 1414 (56 %) to be HIV-negative.
An additional 604 (24 %) who reported not to know
their HIV-status are hereafter considered as HIV-
negative, based on similar risk factor profiles and sensi-
tivity analyses after the exclusion of women with un-
known HIV status. Eighty-four percent of HIV-positive
women were receiving combined anti-retroviral therapy
(cART) (data not shown). Of note, HIV-positive women
represented 11 % of the study population below age 25
but 34 % in those age 45 or older.
Table 2 shows the relationship between HPV positivity
and selected women’s characteristics. In the age-adjusted
model, variables significantly associated with HPV posi-
tivity were age group, occupation, tobacco use, marital
status, number of lifetime sexual partners, history of re-
ceiving cash for sex, the presence of anogenital warts,
HIV positivity, number of pregnancies and contraceptive
use in the last year. Additional adjustment for the two
strongest risk factors, lifetime number of sexual partners
and HIV, attenuated most PRs for HPV positivity, and
the remaining significant associations included age
group (PR for ≥45 vs ≤24 years = 0.45; 95 % CI: 0.37–
0.55), marital status (PR for single versus married = 1.16;
95 % CI: 1.02–1.30), being a farmer (PR for farmers ver-
sus housewives = 0.78; 95 % CI: 0.66–0.92), number of
lifetime sexual partners (PR for ≥3 vs 1 = 1.53; 95 % CI:
1.33–1.77), HIV positivity (PR = 1.54; 95 % CI: 1.36–
1.75), number of pregnancies (PR for ≥4 vs 1 = 0.78;
95 % CI: 0.63–0.97), and use of contraceptive methods
in the last year (PR for any = 0.82; 95 % CI: 0.74–0.91).
Among contraceptive methods, condom did not reach
statistical significance in multi-variate analysis. No sig-
nificant associations with HPV positivity were seen for
body mass index (5 % underweight, 7 % obese), age at
menarche (median = 14 years), age at first sexual inter-
course (median = 18 years), nor difference in age with
partner at first sexual intercourse (median = 5 years
younger) (data not shown).
In addition to total HPV prevalence, HR HPV preva-
lence was also significantly higher among HIV-positive
(32 %) than in HIV-negative (20 %) women. Figure 2
shows prevalence of HR HPV infection, and of cyto-
logical abnormalities among HR HPV-positive women,
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stratified by age group and HIV positivity. PRs for HR
HPV prevalence by HIV-positivity increased with in-
creasing age from 1.6 (95 % CI: 1.3–2.0) in women
below age 25 up to 4.0 (95 % CI: 2.3–7.0) in women aged
45 or older (Fig. 2). The percentage of HR HPV-positive
that had cytological abnormalities was significantly
higher in HIV-positive than HIV-negative women below
age 25 (PR = 1.7, 95 % CI: 1.2–2.6) but similar in older
age groups.
The proportion of women who were positive for
HPV16/18 is shown in Table 3, by cytological diagnosis
and HIV status. Overall, the proportion of HPV16/18-
positive women increased from 5.5 % in normal cytology
up to 40 % in HSIL with no statistically significant
Table 1 Prevalence of human papillomavirus (HPV) types by cytological findings and overall, among 2508 women. Rwanda, 2013–2014
HPV type Normal (N = 2136) ASCUS/ASC-H/LSIL (n = 210) HSIL (n = 45) Total (n = 2508) a
N % N % N % N %
Negative 1510 70.7 56 26.7 2 4.4 1651 65.8
Positive 626 29.3 154 73.3 43 95.6 857 34.2
Multiple 250 11.7 85 40.5 23 51.1 377 15.0
High-risk
16 88 4.1 23 11.0 13 28.9 131 5.2
18 31 1.5 13 6.2 6 13.3 52 2.1
31 35 1.6 12 5.7 4 8.9 54 2.2
33 29 1.4 4 1.9 3 6.7 36 1.4
35 48 2.2 20 9.5 4 8.9 75 3.0
39 22 1.0 10 4.8 2 4.4 37 1.5
45 36 1.7 12 5.7 4 8.9 55 2.2
51 29 1.4 14 6.7 2 4.4 47 1.9
52 50 2.3 20 9.5 3 6.7 76 3.0
56 38 1.8 13 6.2 4 8.9 59 2.4
58 38 1.8 17 8.1 9 20.0 68 2.7
59 28 1.3 6 2.9 0 0.0 36 1.4
68 11 0.5 2 1.0 2 4.4 16 0.6
Any 378 17.7 113 53.8 40 88.9 557 22.2
Possibly high-risk
26 9 0.4 4 1.9 3 6.7 16 0.6
30 11 0.5 6 2.9 1 2.2 18 0.7
34 0 0.0 1 0.5 0 0.0 1 0.0
53 13 0.6 11 5.2 2 4.4 26 1.0
66 39 1.8 18 8.6 1 2.2 63 2.5
67 53 2.5 8 3.8 5 11.1 68 2.7
69 11 0.5 5 2.4 0 0.0 17 0.7
70 30 1.4 8 3.8 0 0.0 38 1.5
73 13 0.6 2 1.0 1 2.2 19 0.8
82 11 0.5 6 2.9 0 0.0 18 0.7
85 4 0.2 1 0.5 1 2.2 6 0.2
Any 167 7.8 60 28.6 10 22.2 248 9.9
Low risk
6 28 1.3 10 4.8 0 0.0 40 1.6
11 15 0.7 4 1.9 0 0.0 20 0.8
Any 282 13.2 59 28.1 10 22.2 368 14.7
aIncluding 117 women with missing/inadequate cytology
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heterogeneity by HIV status (p for heterogeneity = 0.33)
(Table 3).
Of 976 women that underwent VIA, only 5 % were
classified as positive and only one of the 22 HSILs de-
tected in this group of women was VIA-positive (data
not shown).
Discussion
We describe the epidemiology of HPV infection in the
adult female population of Rwanda soon after the coun-
try successfully embarked upon a national programme of
HPV vaccination. Data represent that of an almost en-
tirely vaccine- and screening-naive population and dis-
close a high prevalence of HPV infection (34 %),
particularly among women ≤19 years (54 %). Findings
can be robustly compared with other IARC HPV surveys
that were conducted according to a similar protocol. In
this respect, the age-standardised HR HPV prevalence of
22 % in Rwanda (or 19 % in HIV-negative women) ranks
below that of Guinea (31 %) [10] and Mongolia (25 %)
[11], is similar to the prevalence detected in Nigeria
(18 %) [12] and Vanuatu (19 %) [13], but remains more
elevated than that found in many other areas known to
be at high-risk for cervical cancer, including that in India
(12 %) [14] and Colombia (10 %) [15]. The high preva-
lence of HSIL and cervical cancer in the study popula-
tion is consistent with recent estimates of high cervical
cancer incidence in Rwanda [1].
HPV16 was by far the most frequently detected type
in Rwanda, increasing from 4 % of normal cytology up
to 29 % of HSIL. This agrees with a meta-analysis in
which the proportion of HPV16-positive HSIL in Africa
was 30 %, and lower than in other world regions [16].
Vaccine types HPV16 and/or 18 accounting for 42 % of
HSIL, and a relatively high importance of HPV35 and
HPV58 in Rwanda are also consistent with previous
African studies [16]. The importance of HPV16 and 18
increased with the severity of cytological lesions similarly
in HIV-negative and HIV-positive, and we did not ob-
serve any statistically significant under-representation of
HPV16/18 in HIV-positive HSIL, as has been suggested
by meta-analyses [17].
HIV infection was associated with higher prevalence of
HPV, confirming previous findings from Rwanda [18–20];
sub-Saharan Africa [21–25] and elsewhere [17]. This asso-
ciation persisted after adjustment for lifetime number of
sexual partners, confirming an independent effect of HIV-
infection beyond that of confounding by sexual behaviour.
Indeed, lower CD4+ cell counts (a specific measure of
HIV-related immunosuppression) are known to be nega-
tively associated with the prevalence [26–29], persistence
[30], and cumulative incidence [31] of HPV infection.
In agreement with our present findings, some studies
in sub-Saharan African populations have reported de-
clining HPV prevalence with age [21, 32–34], whereas
others have showed HPV prevalence remaining equally
high [10, 12, 35–37], or even increasing [38] in middle
and old age. Even if it declined, HR HPV prevalence
remained 10–15 % in women age 35 or older in Rwanda,
suggesting that a large proportion of women might test
positive for HPV-based screening and require diagnostic
follow-up and treatment. This problem particularly ap-
plies to HIV-positive women, among whom HR HPV
prevalence decreased less with age than among HIV-
negative women.
Risk factors, other than HIV and age group, associated
with cervical HPV infection were mostly proxies of sex-
ual behaviour, as identified in previous HPV prevalence
Fig. 1 Age-specific prevalence of human papillomavirus (HPV) DNA and of cytological abnormalities among 2508 women. Rwanda, 2013–2014
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Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95 % confidence intervals (CIs)
according to selected characteristics among 2508 women. Rwanda, 2013–2014
Characteristic N women a HPV-positive (%) Adjusted b PR 95 % CI Adjusted c PR 95 % CI
Age-group (years)
≤ 24 1179 500 (42.4) 1 - 1 -
25–34 519 170 (32.8) 0.77 0.67–0.89 0.71 0.62–0.82
35–44 406 101 (24.9) 0.59 0.49–0.70 0.52 0.44–0.63
≥ 45 404 86 (21.3) 0.50 0.41–0.61 0.45 0.37–0.55
Chi2(1) for trend p <0.001 p <0.001
Education (Years)
Non-literate 0–5 325 122 (37.5) 1 - 1 -
Literate 0–5 640 226 (35.3) 0.86 0.73–1.03 0.97 0.82–1.14
Literate 6–10 1123 383 (34.1) 0.88 0.75–1.03 1.00 0.86–1.17
Literate ≥11 420 126 (30.0) 0.85 0.70–1.04 0.99 0.82–1.20
Chi2(1) for trend p =0.199 p =0.849
Occupation
Housewife 964 366 (38.0) 1 - 1 -
Shopkeeper/salesman 391 154 (39.4) 1.13 0.98–1.31 1.03 0.90–1.18
Manual worker 400 132 (33.0) 0.90 0.77–1.06 0.92 0.79–1.08
Teacher/health worker/Student/Clerical staff 188 56 (29.8) 0.93 0.73–1.17 0.92 0.73–1.15
Farmer 532 134 (25.2) 0.72 0.61–0.85 0.78 0.66–0.92
Tobacco use
Never 2276 766 (33.7) 1 - 1 -
Ever 230 91 (39.6) 1.45 1.23–1.71 1.13 0.96–1.32
Marital status
Married or cohabiting 1734 533 (30.7) 1 - 1 -
Single 444 212 (47.8) 1.35 1.20–1.53 1.16 1.02–1.30
Separated/widowed 330 112 (33.9) 1.38 1.17–1.63 1.16 0.98–1.37
Lifetime sexual partnersd
1 1131 294 (26.0) 1 - 1 -
2 701 263 (37.5) 1.45 1.26–1.65 1.37 1.20–1.56
3 281 128 (45.6)
} 1.84e 1.62–2.10 1.53e 1.33–1.77
≥ 4 248 116 (46.8)
Chi2(1) for trend p <0.001 p <0.001
Sexual activity in the last year
Yes 2189 766 (35.0) 1 - 1 -
No 299 84 (28.1) 1.07 0.87–1.30 0.93 0.77–1.14
History of receiving cash for sexd
Never 2333 769 (33.0) 1 - 1 -
Ever 154 85 (55.2) 1.59 1.37–1.84 1.14 0.98–1.33
Evidence of anogenital warts
No 2395 814 (34.0) 1 - 1 -
Yes 113 43 (38.1) 1.35 1.07–1.72 1.09 0.88–1.35
HIV status
Negative 1414 450 (31.8) 1 - 1 -
Unknown 604 166 (27.5) 1.01 0.87–1.18 1.02 0.87–1.18
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surveys. Lifetime number of sexual partners, being
single, and history of receiving cash for sex (albeit
rarely reported), were positively associated with HPV
prevalence in multivariate analyses. Multiparity and
recent use of contraceptives were also significantly
and negatively associated with HPV positivity. Lower
prevalence in farmers than other occupational groups
suggest the possibility of an urban–rural gradient in
the frequency of the infection. Residual confounding
by sexual behaviour on the association with occupa-
tion, multiparity, and contraceptive use is difficult to
rule out [39, 40].
Fig. 2 Age-specific prevalence of HR HPV infection, and of cytological abnormalities among HR HPV-positive women, stratified by HIV status among
2508 women. Rwanda, 2013–2014
Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95 % confidence intervals (CIs)
according to selected characteristics among 2508 women. Rwanda, 2013–2014 (Continued)
Positive 490 241 (49.2) 1.84 1.65–2.06 1.54 1.36–1.75
Number of pregnancies
Nulliparous 237 101 (42.6) 1.15 0.97–1.36 0.99 0.85–1.15
1 804 327 (40.7) 1 - 1 -
2-3 840 285 (33.9) 0.94 0.83–1.08 0.85 0.75–0.97
≥ 4 616 141 (22.9) 0.85 0.67–1.06 0.78 0.63–0.97
Chi2(1) for trend p =0.010 p =0.006
Contraceptive use in the last year
No 1146 422 (36.8) 1 - 1 -
Yes 1359 432 (31.8) 0.80 0.72–0.89 0.82 0.74–0.91
Hormonal 1005 339 (33.7) 0.82 0.73–0.92 0.84 0.75–0.96
Intra Uterine Device 185 54 (29.2) 0.79 0.62–1.00 0.79 0.62–1.00
Condom 72 25 (34.7) 0.92 0.67–1.27 0.86 0.64–1.16
Other/two or more of above 97 14 (14.4) 0.48 0.29–0.78 0.45 0.26–0.78
aSome figures do not add up to the total due to missing values
bAdjusted for age as appropriate
cAdjusted for age, HIV status and lifetime sexual partners as appropriate
dthree virgins excluded
ePR ratio is calculated for “three lifetime sexual partners or more”
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Although only 2 % of study participants reported a prior
Pap smear, the current study coincided with the initiation
of screening and treatment programmes based on VIA,
and/or testing for HPV DNA with careHPV (QIAGEN,
Hilden, Germany) with use of VIA to triage HPV-positives
for treatment [41]. A potential warning about the per-
formance of VIA in this setting comes from the finding
that, despite very high HR HPV prevalence, VIA detected
abnormalities in only 5 % of women in this high-risk
population, and missed the vast majority of HSIL. This
mirrors findings from other IARC HPV surveys [10, 42].
This study has strengths and weaknesses. Strengths in-
clude the relatively large number of women, especially
young women, and the use of high-quality HPV testing
and liquid-based cytology. HPV infection is asymptomatic
and self-selection of women by level of HPV risk is un-
likely to have occurred. The large number of HIV-positive
women in our study will allow the opportunity to estimate
HPV vaccine effectiveness in this high-risk group separ-
ately but also raises the question of whether our study
population is representative of the general female popula-
tion in Kigali, and Rwanda as a whole. HIV-positive
women are over-represented in our survey in comparison
to the general population [43]. In particular, HIV-positive
women (in the vast majority under cART treatment) were
clearly more willing to accept screening invitations, or to
be spontaneously seeking medical care, than HIV-negative
women and represented approximately one third of study
women age 35 or older. Had overall age-standardised HR
HPV prevalence been estimated among HIV-negative
women only, however, findings would have not been very
different: 19 % instead of 22 %.
Conclusions
The findings of this study confirm Rwanda to be a setting
of high prevalence of HPV and cervical disease that is
worsened by HIV co-infection. These data will serve as a
robust baseline for evaluations of HPV vaccine programme
effectiveness in future cohorts of vaccinated girls.
Ethics approval and consent to participate
The present study had the approval of the Health
Research Committee and Rwanda National Ethical
Committee of the Rwandan Ministry of Health and the
IARC Ethics Committee.
Informed consent was obtained from all study
participants.
Consent for publication
Not applicable.
Availability of data and materials
The datasets supporting the conclusions of this article
are included within the article.
Abbreviations
ASCUS/ASC-H/AGUS/LSIL: atypical squamous cells of undetermined
significance, atypical squamous cells cannot exclude high-grade lesion or atyp-
ical glandular cells of undetermined significance, low-grade squamous intrae-
pithelial lesions; cART: combined anti-retroviral therapy; CI: confidence interval;
HPV: human papillomavirus; HR: high-risk; HSIL: high-grade squamous
intraepithelial lesions; IARC: International Agency for Research on Cancer;
LR: low-risk; PR: prevalence ratio; VIA: visual inspection with acetic acid.
Competing interests
P.J.F. Snijders has Honoraria from Speakers Bureau from Roche, Gen-Probe,
Qiagen, Abbott and Seegene and has a minority stake in Self-screen. No
competing interests were disclosed by the other authors.
Authors’ contributions
GC and SF conceived the study protocol. FN, MG and AG were involved in the
development of the study methodology and infrastructure in Rwanda. MCU
supervised the study protocol and data entry in Rwanda. IB, FL and VT were
responsible for designing the electronic supports for data acquisition and/or
statistical analyses. PS and AU were responsible for HPV testing and cytological
reading, respectively. GC wrote the first draft of the manuscript. All authors
were involved in the interpretation of the analyses and gave input to the final
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Marcelline Mahirwe and Evodie Mudaheranwa, the
staff of Muhima Hospital, the staff in the health centres of Muhima,
Butamwa, Rugarama, Mwendo, Corum, Gitega, Kabusunzu and Biryogo for
their contribution to the field work in Rwanda. We also acknowledge the
help of Dr Venerand Bigirimana, Pathologist at Kigali University Hospital for
histological confirmation of biopsies, and Veronique Chabanis and Susan
Gamon at IARC for administrative assistance.
Funding
The support for this project came from the Rwandan Ministry of Health, the
International Agency for Research on Cancer and grants from the Bill &
Melinda Gates Foundation, USA (grant numbers 35537 and OPP1053353).
The Bill & Melinda Gates Foundation did not have any role in the writing
process of this manuscript.
Table 3 Positivity for human papillomavirus (HPV)16/18 among 2508 women, according to cytological findings and HIV status.
Rwanda, 2013–2014
Cytology HIV negative HIV positive Total
N HPV16/18-pos n (%) N HPV16/18-pos n (%) N HPV16/18-pos n (%)
Normal 1749 91 (5.2) 387 26 (6.7) 2136 117 (5.5)
ASCUS/ASC-H/LSIL 146 26 (17.8) 64 8 (12.5) 210 34 (16.2)
HSIL 27 11 (40.7) 18 7 (38.9) 45 18 (40.0)
p-value for heterogeneity by HIV statusa = 0.33
alog-likelihood ratio test (see methods)
Ngabo et al. BMC Infectious Diseases  (2016) 16:225 Page 8 of 10
Author details
1Ministry of Health of Rwanda, Kigali, Rwanda. 2Université Libre de Bruxelles,
Ecole de Santé Publique, Brussels, Belgium. 3International Agency for
Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France.
4Department of Pathology, VU University Medical Center, De Boelelaan 1117,
1081 HV Amsterdam, The Netherlands. 5Unit of Cancer Epidemiology,
Department of Medical Sciences, University of Turin, Turin, Italy. 6Harvard
Medical School, Boston, MA, USA. 7Geisel School of Medicine, Dartmouth,
Hanover, USA.
Received: 2 October 2015 Accepted: 5 May 2016
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M,
Parkin DM, Forman D, and Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence
and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France:
International Agency for Research on Cancer; http://globocan.iarc.fr.
Accessed 20 June 15.
2. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F.
Achieving high coverage in Rwanda’s national human papillomavirus
vaccination programme. Bull World Health Organ. 2012;90:623–8.
3. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT,
Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S,
Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, and the
IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human
papillomavirus types in cytologically normal women in the International
Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.
Lancet. 2005;366:991–8.
4. Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ,
Walboomers JM. Processing of long-stored archival cervical smears for
human papillomavirus detection by the polymerase chain reaction. Br J
Cancer. 1995;72:412–7.
5. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH,
Fransen-Daalmeijer N, Meijer CJ. Distribution of 37 mucosotropic HPV types
in women with cytologically normal cervical smears: the age-related
patterns for high-risk and low-risk types. Int J Cancer. 2000;87:221–7.
6. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ,
Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables
rapid and high-throughput identification of human papillomavirus
genotypes. J Clin Microbiol. 2002;40:779–87.
7. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;
90:1–636. http://monographs.iarc.fr/ENG/Monographs/vol90/index.php.
Accessed 20 June 15.
8. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-A
framework for cytology reporting increases efficacy of screening upon
standardisation since 1996. J Clin Pathol. 2004;57:388–93.
9. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus
and cervical cancer. Lancet. 2013;382:889–99.
10. Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van
Kemenade FJ, Snijders PJ, Meijer CJ, Franceschi S. HPV infection in women
with and without cervical cancer in Conakry, Guinea. Br J Cancer.
2009;101:202–8.
11. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D,
Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ,
Franceschi S, Pawlita M. Human papillomavirus infection in Ulaanbaatar,
Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev.
2008;17:1731–8.
12. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A,
Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJ, Meijer CJ, Franceschi S.
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a
population-based study. Br J Cancer. 2004;90:638–45.
13. Aruhuri B, Tarivonda L, Tenet V, Sinha R, Snijders PJ, Clifford G, Pang J,
McAdam M, Meijer CJ, Frazer IH, Franceschi S. Prevalence of cervical Human
Papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res (Phila).
2012;5:746–53.
14. Franceschi S, Rajkumar R, Snijders PJF, Arslan A, Mahé C, Plummer M,
Sankaranarayanan R, Cherian J, Meijer CJLM, Weiderpass E. Papillomavirus
infection in rural women in southern India. Br J Cancer. 2005;92:601–6.
15. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M,
Franceschi S, Meijer CJ, Arslan A, Munoz N, and the HPV Study Group.
Prevalence and determinants of HPV infection among Colombian women
with normal cytology. Br J Cancer. 2002;87:324–33.
16. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM.
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis
from cervical infection to cancer. Int J Cancer. 2012;131:2349–59.
17. Clifford GM, Goncalves MA, Franceschi S, for the HPV and HIV Study Group.
Human papillomavirus types among women infected with HIV: a meta-
analysis. AIDS. 2006;20:2337–44.
18. Sinayobye J, Sklar M, Hoover DR, Shi Q, Dusingize JC, Cohen M,
Mutimura E, Asiimwe-Kateera B, Castle PE, Strickler H, Anastos K.
Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV)
infection among HIV-infected and Uninfected Rwandan women:
implications for hrHPV-based screening in Rwanda. Infect Agent
Cancer. 2014;9:40.
19. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Mutimura E,
Cajigas A, Bigirimani V, Cai X, Rwamwejo J, Vuolo M, Cohen M, Castle PE.
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-
uninfected Rwandan women. J Infect Dis. 2009;199:1851–61.
20. Veldhuijzen NJ, Braunstein SL, Vyankandondera J, Ingabire C, Ntirushwa J,
Kestelyn E, Tuijn C, Wit FW, Umutoni A, Uwineza M, Crucitti T, van de
Wijgert JH. The epidemiology of human papillomavirus infection in HIV-
positive and HIV-negative high-risk women in Kigali, Rwanda. BMC Infect
Dis. 2011;11:333.
21. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA,
Chipato T, Ngwalle S, Munjoma M, Shah KV. HPV-based cervical cancer
screening in a population at high risk for HIV infection. Int J Cancer.
2000;85:206–10.
22. Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D,
Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R. Determinants of
incidence and clearance of high-risk human papillomavirus infections in
rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev. 2008;17:1300–7.
23. Akarolo-Anthony SN, Al-Mujtaba M, Famooto AO, Dareng EO, Olaniyan OB,
Offiong R, Wheeler CM, Adebamowo CA. HIV associated high-risk HPV
infection among Nigerian women. BMC Infect Dis. 2013;13:521.
24. Hanisch RA, Sow PS, Toure M, Dem A, Dembele B, Toure P, Winer RL,
Hughes JP, Gottlieb GS, Feng Q, Kiviat NB, Hawes SE. Influence of HIV-1
and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in
women from Senegal, West Africa. J Clin Virol. 2013;58:696–702.
25. Dartell M, Rasch V, Munk C, Kahesa C, Mwaiselage J, Iftner T, Kjaer SK.
Risk factors for high-risk human papillomavirus detection among HIV-
negative and HIV-positive women from Tanzania. Sex Transm Dis.
2013;40:737–43.
26. Chaturvedi AK, Dumestre J, Gaffga AM, Mire KM, Clark RA, Braly PS, Dunlap K,
Beckel TE, Hammons AF, Kissinger PJ, Hagensee ME. Prevalence of human
papillomavirus genotypes in women from three clinical settings. J Med Virol.
2005;75:105–13.
27. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A,
Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, Bacon M, Schuman P,
Levine AM, Durante AJ, Gange S, Melnick S, Burk RD. Human papillomavirus
type 16 and immune status in human immunodeficiency virus-seropositive
women. J Natl Cancer Inst. 2003;95:1062–71.
28. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS,
Hall C, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X,
Schlecht NF, Melnick S, Palefsky JM. Natural history and possible
reactivation of human papillomavirus in human immunodeficiency
virus-positive women. J Natl Cancer Inst. 2005;97:577–86.
29. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, Minkoff H,
Hall CB, Bacon MC, Levine AM, Watts DH, Silverberg MJ, Xue X, Melnick SL,
Strickler HD. Incidence of cervical squamous intraepithelial lesions
associated with HIV serostatus, CD4 cell counts, and human papillomavirus
test results. JAMA. 2005;293:1471–6.
30. Rowhani-Rahbar A, Hawes SE, Sow PS, Toure P, Feng Q, Dem A, Dembele B,
Critchlow CW, N'Doye I, Kiviat NB. The impact of HIV status and type on the
clearance of human papillomavirus infection among Senegalese women. J
Infect Dis. 2007;196:887–94.
31. Massad LS, Xie X, Burk R, Keller MJ, Minkoff H, D’Souza G, Watts DH, Palefsky J,
Young M, Levine AM, Cohen M, Strickler HD. Long-term cumulative detection
of human papillomavirus among HIV seropositive women. AIDS.
2014;28:2601–8.
32. Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, Li C, Lorincz A,
Meehan MP, Wabwire-Mangen F, Gray RH. Use of a hybrid capture assay of
Ngabo et al. BMC Infectious Diseases  (2016) 16:225 Page 9 of 10
self-collected vaginal swabs in rural Uganda for detection of human
papillomavirus. J Infect Dis. 1999;180:1316–9.
33. Castellsagué X, Menendez C, Loscertales MP, Kornegay JR, dos Santos F,
Gomez-Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P.
Human papillomavirus genotypes in rural Mozambique. Lancet.
2001;358:1429–30.
34. de Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S,
Vansteelandt S, Quint W, Kleter B, Van Marck E, Temmerman M. Distribution
of human papillomavirus in a family planning population in Nairobi, Kenya.
Sex Transm Dis. 2003;30:137–42.
35. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M,
Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M.
The age-specific prevalence of human papillomavirus and risk of cytologic
abnormalities in rural Nigeria: Implications for screen-and-treat strategies. Int
J Cancer. 2012;130:2111–7.
36. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human
papillomavirus DNA testing for cervical cancer screening in low-resource
settings. J Natl Cancer Inst. 2000;92:818–25.
37. Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S,
Gelder CM, Walraven G, Borysiewicz LK. Cervical human papillomavirus
infection and squamous intraepithelial lesions in rural Gambia, West Africa:
viral sequence analysis and epidemiology. Br J Cancer. 2005;93:1068–76.
38. Xi LF, Toure P, Critchlow CW, Hawes SE, Dembele B, Sow PS, Kiviat NB.
Prevalence of specific types of human papillomavirus and cervical
squamous intraepithelial lesions in consecutive, previously unscreened,
West-African women over 35 years of age. Int J Cancer. 2003;103:803–9.
39. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT,
Ferreccio C, Matos E, Posso H, de SS, Shin HR, Sukvirach S, Lazcano-Ponce E,
Ronco G, Rajkumar R, Qiao YL, Munoz N, Franceschi S. Reproductive factors, oral
contraceptive use, and human papillomavirus infection: pooled analysis of the
IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev.
2006;15:2148–53.
40. Vaccarella S, Franceschi S, Herrero R, Munoz N, Snijders PJF, Clifford GM,
Smith JS, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjose S, Molano M,
Matos E, Ferreccio C, Anh PTH, Thomas JO, Meijer CJLM, and the IARC HPV
Prevalence Surveys Study Group. Sexual behavior, condom use and HPV:
pooled analysis of the International Agency for Research on Cancer HPV
Prevalence Surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:326–33.
41. Binagwaho A, Ngabo F, Wagner CM, Mugeni C, Gatera M, Nutt CT,
Nsanzimana S. Integration of comprehensive women’s health programmes
into health systems: cervical cancer prevention, care and control in Rwanda.
Bull World Health Organ. 2013;91:697–703.
42. Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, Zhang YZ, Li LK, Wu RF,
De VH, Plummer M, Qiao YL, Clifford G. Different cervical cancer screening
approaches in a Chinese multicentre study. Br J Cancer. 2009;100:532–7.
43. Rwanda Biomedical Center. Rwanda Global AIDS Response Progress Report
2014. Rwanda, Kigali: Republic of Rwanda, Ministry of Health; http://www.
unaids.org/sites/default/files/country/documents/RWA_narrative_report_
2014.pdf. Accessed 20 May 15
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ngabo et al. BMC Infectious Diseases  (2016) 16:225 Page 10 of 10
